156 related articles for article (PubMed ID: 25715767)
1. Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors.
Oh DY; Kim TM; Han SW; Shin DY; Lee YG; Lee KW; Kim JH; Kim TY; Jang IJ; Lee JS; Bang YJ
Cancer Res Treat; 2016 Jan; 48(1):28-36. PubMed ID: 25715767
[TBL] [Abstract][Full Text] [Related]
2. A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer.
Jeong H; Hong YS; Kim JE; Lim HS; Ahn JB; Shin SJ; Park YS; Kim ST; Han SW; Kim TY; Kim TW
Invest New Drugs; 2021 Oct; 39(5):1335-1347. PubMed ID: 33829355
[TBL] [Abstract][Full Text] [Related]
3. Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors.
Oh DY; Lee SH; Han SW; Kim MJ; Kim TM; Kim TY; Heo DS; Yuasa M; Yanagihara Y; Bang YJ
Cancer Res Treat; 2015 Oct; 47(4):607-15. PubMed ID: 25715763
[TBL] [Abstract][Full Text] [Related]
4. Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors.
Bendell JC; Patel MR; Infante JR; Kurkjian CD; Jones SF; Pant S; Burris HA; Moreno O; Esquibel V; Levin W; Moore KN
Cancer; 2015 Apr; 121(7):1056-63. PubMed ID: 25411085
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the vascular-disrupting agent CKD-516 (NOV120401) in patients with refractory solid tumors.
Kim HK; Kang JW; Park YW; Kim JY; Kim M; Kim SJ; Kim SM; Ho Ryu K; Yoon S; Kim Y; Cho JY; Lee KS; Yun T; Kim K; Kwak MH; Kim TS; Chung J; Park JW
Pharmacol Res Perspect; 2020 Apr; 8(2):e00568. PubMed ID: 32162844
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of pazopanib plus TH-302 in advanced solid tumors.
Riedel RF; Meadows KL; Lee PH; Morse MA; Uronis HE; Blobe GC; George DJ; Crawford J; Niedzwiecki D; Rushing CN; Arrowood CC; Hurwitz HI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):611-619. PubMed ID: 28238078
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors.
Beg MS; Brenner AJ; Sachdev J; Borad M; Kang YK; Stoudemire J; Smith S; Bader AG; Kim S; Hong DS
Invest New Drugs; 2017 Apr; 35(2):180-188. PubMed ID: 27917453
[TBL] [Abstract][Full Text] [Related]
9. First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors.
Li T; LoRusso P; Maitland ML; Ou SH; Bahceci E; Ball HA; Park JW; Yuen G; Tolcher A
J Hematol Oncol; 2016 Mar; 9():23. PubMed ID: 26966027
[TBL] [Abstract][Full Text] [Related]
10. Phase I Dose-Escalation Study of SCB01A, a Microtubule Inhibitor with Vascular Disrupting Activity, in Patients with Advanced Solid Tumors.
Shiah HS; Chiang NJ; Lin CC; Yen CJ; Tsai HJ; Wu SY; Su WC; Chang KY; Wang CC; Chang JY; Chen LT
Oncologist; 2021 Apr; 26(4):e567-e579. PubMed ID: 33245172
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
[TBL] [Abstract][Full Text] [Related]
12. First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors.
Elez E; Gomez-Roca C; Soto Matos-Pita A; Argiles G; Valentin T; Coronado C; Iglesias J; Macarulla T; Betrian S; Fudio S; Zaragoza K; Tabernero J; Delord JP
Invest New Drugs; 2019 Aug; 37(4):674-683. PubMed ID: 30411218
[TBL] [Abstract][Full Text] [Related]
13. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
Bendell JC; Rodon J; Burris HA; de Jonge M; Verweij J; Birle D; Demanse D; De Buck SS; Ru QC; Peters M; Goldbrunner M; Baselga J
J Clin Oncol; 2012 Jan; 30(3):282-90. PubMed ID: 22162589
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
Ricart AD; Ashton EA; Cooney MM; Sarantopoulos J; Brell JM; Feldman MA; Ruby KE; Matsuda K; Munsey MS; Medina G; Zambito A; Tolcher AW; Remick SC
Cancer Chemother Pharmacol; 2011 Oct; 68(4):959-70. PubMed ID: 21305290
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.
Strickler JH; Weekes CD; Nemunaitis J; Ramanathan RK; Heist RS; Morgensztern D; Angevin E; Bauer TM; Yue H; Motwani M; Parikh A; Reilly EB; Afar D; Naumovski L; Kelly K
J Clin Oncol; 2018 Nov; 36(33):3298-3306. PubMed ID: 30285518
[TBL] [Abstract][Full Text] [Related]
16. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor OSI-906 in patients with advanced solid tumors.
Jones RL; Kim ES; Nava-Parada P; Alam S; Johnson FM; Stephens AW; Simantov R; Poondru S; Gedrich R; Lippman SM; Kaye SB; Carden CP
Clin Cancer Res; 2015 Feb; 21(4):693-700. PubMed ID: 25208878
[TBL] [Abstract][Full Text] [Related]
18. A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors.
Infante JR; Mendelson DS; Burris HA; Bendell JC; Tolcher AW; Gordon MS; Gillenwater HH; Arastu-Kapur S; Wong HL; Papadopoulos KP
Invest New Drugs; 2016 Apr; 34(2):216-24. PubMed ID: 26924128
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.
Campone M; Isambert N; Bourbouloux E; Maury S; Monin-Baroille P; Berille J; Fumoleau P
Cancer Chemother Pharmacol; 2007 Apr; 59(5):689-95. PubMed ID: 17031647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
